Mobile Health Technology for Atrial Fibrillation Management
This study is testing a digital tool called the Corrie Virtual Atrial Fibrillation Management Program. This program aims to help people with atrial fibrillation (AFib), a type of irregular heartbeat, learn about their condition, stick to treatments, and manage AFib episodes. Researchers want to see if this digital tool can improve your quality of life and reduce how often you experience AFib. You might be able to join if you are 18 or older, have paroxysmal (short-lasting) or persistent (longer-lasting) AFib, and have a BMI (Body Mass Index) of 27.0 or higher. People with permanent AFib, severe heart valve disease, moderate mitral valve stenosis, or who have had prior heart surgery cannot participate. The study will measure how many participants are free from documented atrial tachyarrhythmia (fast heart rhythms) between 91 and 365 days.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 248 participants to evaluate the digital management tool.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to see if they are free from documented atrial tachyarrhythmia between 91 and 365 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Mobile Health Technology-Enabled AFib Management
At a glance
Conditions
NCT06500988
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Johns Hopkins Bayview Medical Center
Baltimore, Marylandstudy coordinator listed
Recruiting
Johns Hopkins Outpatient Center
Baltimore, Marylandstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Nino Isakadze, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Participants Freedom from documented atrial tachyarrhythmia91 to 365 days
Freedom from documented atrial tachyarrhythmia (atrial fibrillation/atrial flutter/atrial tachycardia) episodes of ≥30 seconds between 91 and 365 days after catheter ablation, on or off antiarrhythmic drugs.